GERON CORP 8-K

What Happened

• Geron Corporation (filed 8-K on March 26, 2026; Item 5.02) announced that on March 25, 2026 its Board elected Patricia S. Andrews and Constantine Chinoporos as Class III directors, each effective immediately. Their terms expire at the Company’s 2026 Annual Meeting of Stockholders.
• Ms. Andrews was also appointed to the Board’s Audit Committee. Both directors will be paid cash and equity compensation under Geron’s standard non-employee director program and will enter the Company’s standard indemnification agreement.

Key Details

• Election date: March 25, 2026; filing date: March 26, 2026 (8-K Item 5.02).
• Term: both are Class III directors with terms expiring at the 2026 Annual Meeting.
• Committee assignment: Patricia S. Andrews named to the Audit Committee upon her election.
• Compensation & protections: both will receive cash and equity per Geron’s standard director compensation (see 2025 proxy), and will be covered by the Company’s standard indemnification agreement (may cover attorneys’ fees, judgments, fines, settlements).

Why It Matters

• Board composition: adding two independent directors can affect corporate oversight and governance. Andrews’ background in oncology commercialization and audit experience (former CEO/operating roles and prior audit committee service) may strengthen commercial and financial oversight. Chinoporos’ deal-making and business-development background (senior business roles and recent C-suite experience in biopharma) adds M&A and partnership experience to the Board.
• For investors: this is a governance update — not a management change or a financial report. Compensation follows existing policies and there are no special arrangements disclosed between the new directors and other parties.